Form 4: Alto Neuroscience Director Receives Stock Options

Alto Neuroscience, Inc. Director Ramiro Sanchez was granted 3,806 stock options with an exercise price of $16.59, vesting quarterly throughout 2026.

Summary

• Director Ramiro Sanchez of Alto Neuroscience, Inc. (ANRO) was granted 3,806 stock options.
• The options have an exercise price of $16.59 per share.
• The grant date for these options was January 2, 2026.
• The options will expire on January 1, 2036.
• The vesting schedule is quarterly in 2026: 952 shares on March 31, 2026; 951 shares on June 30, 2026; 952 shares on September 30, 2026; and 951 shares on December 31, 2026, contingent on continuous service.
• These options were issued as part of the company's Non-Employee Director Compensation Policy, in lieu of $45,000 in retainer fees.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. This is a routine compensation disclosure, which is generally a positive sign of corporate governance and alignment, but does not indicate significant operational news.

Positives

• The grant of stock options aligns the director's interests with shareholders, encouraging long-term value creation.
• The compensation structure for non-employee directors includes equity, which is a common best practice for corporate governance.

Risks

• The vesting of options is subject to the reporting person's continuous service, meaning unvested options could be forfeited if service ceases.
• The value of the options is dependent on the future stock price of Alto Neuroscience, Inc., introducing market risk.

Future Outlook

The company's compensation policy for non-employee directors includes long-term equity incentives, indicating a strategy to align director interests with the company's future performance and shareholder value creation.

Management Comments

• The option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $45,000.

Industry Context

Granting stock options to non-employee directors is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology and neuroscience, to attract and retain qualified board members and align their incentives with long-term company success.

Comparison to Industry Standards

• The use of stock options as a component of non-employee director compensation is a common practice across publicly traded companies, particularly in growth-oriented sectors like neuroscience.
• The vesting schedule, typically over one year or more, is standard for equity grants to ensure continued service and long-term alignment.
• The value of the options granted in lieu of $45,000 in retainer fees is within typical ranges for director compensation in similar-sized companies, though specific comparisons would require detailed peer group analysis.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options aligns the director's interests with shareholders, potentially encouraging decisions that enhance long-term stock value. It also represents a non-cash compensation expense.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.

Next Steps

• Director Ramiro Sanchez will continue to provide service to Alto Neuroscience, Inc. to ensure the vesting of the options.
• The company will continue to operate under its Non-Employee Director Compensation Policy for director compensation.

Key Dates

Recommendation

This Form 4 filing details a routine stock option grant to a non-employee director as part of their compensation policy. While it demonstrates standard corporate governance practices and aligns director incentives with shareholder value, it does not contain information significant enough to warrant a change in investment recommendation. It's a neutral event for the stock's immediate outlook.

Keywords

Alto Neuroscience, ANRO, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Grant, Vesting